Guardant Health director converts 264 RSUs to stock

Guardant Health director Roberto Mignone exercised a restricted stock unit award on July 21, 2026, converting 264 Restricted Stock Units into 264 shares of Common Stock at $0.00 per share.

Rhea-AI Filing Summary

Guardant Health director Roberto Mignone exercised a restricted stock unit award on July 21, 2026, converting 264 Restricted Stock Units into 264 shares of Common Stock at $0.00 per share. Following this transaction, he directly holds 9,746 Common shares and 7,128 Restricted Stock Units. The RSU grant, awarded on November 8, 2024, vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the subsequent three years. The transaction was not marked as made under a Rule 10b5-1 trading plan, as the related checkbox was left unchecked.

Insider Trade Summary

264 shares exercised/converted

Exercise 2 txns

Insider MIGNONE ROBERTO

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F1, F2	264	$0.00	$0.00
Exercise	Common Stock	264	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 7,128 contracts (Direct); Common Stock — 9,746 shares (Direct)

Footnotes (2)

1. F1. The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter.
2. F2. Not applicable for Restricted Stock Units.

Key Figures

RSUs converted: 264 Restricted Stock Units Common shares acquired: 264 shares Common shares held after: 9,746 shares +4 more

7 metrics

RSUs converted 264 Restricted Stock Units Exercise or conversion on July 21, 2026

Common shares acquired 264 shares Shares received from RSU conversion on July 21, 2026

Common shares held after 9,746 shares Direct Common Stock ownership following the transaction

RSUs remaining 7,128 Restricted Stock Units Restricted Stock Units held after the reported conversion

RSU grant date November 8, 2024 Grant date of the reported restricted stock unit award

Initial vesting tranche 25% of award Portion of RSU award that vested on October 21, 2025

Remaining vesting period 3 years Remaining 75% of RSUs vests monthly over this period

Key Terms

Restricted Stock Units, derivative security, vests monthly

3 terms

Restricted Stock Units financial

"The restricted stock unit award granted on November 8, 2024 vests over a four-year period"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"transaction code description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vests monthly financial

"the remaining 75% vests monthly for the three-year period thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Guardant Health (GH) director Roberto Mignone report?

Roberto Mignone reported converting 264 Restricted Stock Units into 264 shares of Guardant Health Common Stock on July 21, 2026. The exercise price was reported as $0.00 per share, reflecting a standard RSU settlement into fully vested common shares.

How many Guardant Health (GH) common shares does Roberto Mignone own after this Form 4?

After the reported transaction, Roberto Mignone directly owns 9,746 shares of Guardant Health Common Stock. These holdings reflect the addition of 264 shares from the RSU conversion, as disclosed in the filing’s post-transaction ownership figure.

What is Roberto Mignone’s remaining RSU balance at Guardant Health (GH)?

Following the July 21, 2026 conversion, Roberto Mignone holds 7,128 Restricted Stock Units. This remaining balance continues to vest over time pursuant to the original November 8, 2024 grant’s four-year vesting schedule described in the disclosure footnotes.

What are the vesting terms of the November 8, 2024 RSU grant at Guardant Health (GH)?

The November 8, 2024 RSU grant vests over four years. 25% of the shares vested on October 21, 2025, and the remaining 75% vests monthly over the following three-year period, resulting in gradual monthly delivery of additional vested units.

Was Roberto Mignone’s Guardant Health (GH) transaction executed under a Rule 10b5-1 trading plan?

The transaction was not indicated as being under a Rule 10b5-1 trading plan. The specific Rule 10b5-1 checkbox associated with the reported trades was left unchecked, suggesting no pre-arranged trading plan status was claimed for this RSU conversion event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/22/2026 - 05:16 PM Accepted by SEC EDGAR 07/22/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MIGNONE ROBERTO

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/21/2026		M		264	A	$0	9,746	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	07/21/2026		M			264	(1)	(2)	Common Stock	264	$0	7,128	D

Explanation of Responses:

1. The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Roberto A. Mignone	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)